Results 281 to 290 of about 9,805,880 (332)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Gene Therapy for Glomerular Disease.

J Am Soc Nephrol
Saleem MA.
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Short- and long-term outcomes in critically ill patients with primary glomerular disease: a case‒control study. [PDF]

BMC Nephrol
Coutinho NFR, Libório AB.
europepmc   +1 more source

Differentiated metabolomic profiling reveals plasma amino acid signatures for primary glomerular disease. [PDF]

Amino Acids
Wang J, Zhou C, Lu L, Wang S, Zhang Q, Liu Z.   +5 more
europepmc   +1 more source

Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease. [PDF]

Am J Kidney Dis
de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, Morgan P, Meliambro K, Egerman M, Ray J, Parker T, Levine D, Seshan S, Bardash Y, Horowitz B, Kent CA, Shaw MM, Perlman A, Moledina DG, Coca SG, Campbell KN.   +20 more
europepmc   +1 more source

Pregnancy in Glomerular Disease: From Risk Identification to Counseling and Management. [PDF]

J Clin Med
Maressa V, Longhitano E, Casuscelli C, Di Carlo S, Peritore L, Santoro D.   +5 more
europepmc   +1 more source

Type I IFN in Glomerular Disease: Scarring beyond the STING. [PDF]

Int J Mol Sci
Jimenez-Uribe AP, Mangos S, Hahm E.
europepmc   +1 more source

Complementary and Alternative Medicine Use and Glomerular Disease: A Contemporary Case Series. [PDF]

Kidney Med
Devaraju PK, Seshadri J, Balasubramanian CM, Kurien AA, Senthilkumaran G, Rajarathinam VD, Jibia VS, Murugesan V, Lamech TM, Thanigachalam D, Ramanathan S, Alavudeen SS, Dakshinamoorthy S, Mookaiah S, Gopalakrishnan N.   +14 more
europepmc   +1 more source